CeNeS Updates M6G Program

UK’s CeNeS Pharmaceuticals has completed preparations for the U.S. Phase III program of M6G, a treatment for post-operative pain.

CeNeS has completed a Phase I pharmacokinetic study and a Phase I metabolism study. The company also has enrolled the final patient in its renal-impairment study.

The company said it expects to announce a licensing deal in 2008.